First Celiac Disease Patient Dosed in Calypso IL-15 Monoclonal Antibody Trial
Calypso Biotech, a leading biotechnology company in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of the dosing
Read moreCalypso Biotech, a leading biotechnology company in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of the dosing
Read moreReal-world data has shown the Vaxzevria vaccine (formerly AZD1222), co-developed by AstraZeneca, the University of Oxford and its spin-out company,
Read moreMerck, also known as MSD, revealed that the U.S. Food and Drug Administration (FDA) has authorised VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate
Read moreCureVac N.V, a global biopharmaceutical company creating a novel class of revolutionary medicines based on messenger ribonucleic acid (mRNA), revealed
Read morePfizer announced on Wednesday, the acquisition of Amplyx Pharmaceuticals, Inc., a privately-owned company focused on the engineering of treatments for
Read moreEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) revealed that it has invested in OxVax, a new immuno-oncology organization
Read moreHistoSure, in cooperation with Charles River Discovery Research Services Germany, now offers a set of groundbreaking highly validated species-specific antibodies
Read moreFrench pharma giant Sanofi is set to acquire Tidal Therapeutics for $470m, adding the biotech’s novel mRNA-based research platform with
Read moreBristol Myers Squibb announced positive results from a Phase 3 Trial, which showed that neoadjuvant treatment with three cycles of
Read moreExscientia, a leading artificial intelligence (AI) driven pharmatech company based in Oxford, England, announced that the first AI-designed molecule for
Read more